EVA1A

Summary

EVA1A (eva-1 homolog A, regulator of programmed cell death, HGNC:25816) is a protein-coding gene on chromosome 2p12, encoding Protein eva-1 homolog A (Q9H8M9). Acts as a regulator of programmed cell death, mediating both autophagy and apoptosis.

Predicted to act upstream of or within several processes, including TOR signaling; cardiac left ventricle morphogenesis; and connective tissue replacement. Located in intracellular membrane-bounded organelle and plasma membrane.

Source: NCBI Gene 84141 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 51 total
• MANE Select transcript: NM_001135032

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25816
Approved symbol	EVA1A
Name	eva-1 homolog A, regulator of programmed cell death
Location	2p12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13391
Ensembl gene	ENSG00000115363
Ensembl biotype	protein_coding
OMIM	618990
Entrez	84141

Gene structure

Transcript identifiers

Ensembl transcripts: 67 — 63 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000233712, ENST00000393913, ENST00000410010, ENST00000410071, ENST00000410113, ENST00000432649, ENST00000452003, ENST00000485891, ENST00000486489, ENST00000486696, ENST00000490746, ENST00000910257, ENST00000910258, ENST00000910259, ENST00000910260, ENST00000910261, ENST00000910262, ENST00000910263, ENST00000910264, ENST00000910265, ENST00000910266, ENST00000910267, ENST00000910268, ENST00000910269, ENST00000910270, ENST00000910271, ENST00000910272, ENST00000910273, ENST00000910274, ENST00000910275, ENST00000910276, ENST00000910277, ENST00000910278, ENST00000910279, ENST00000910280, ENST00000910281, ENST00000910282, ENST00000910283, ENST00000910284, ENST00000910285, ENST00000910286, ENST00000910287, ENST00000910288, ENST00000910289, ENST00000910290, ENST00000910291, ENST00000910292, ENST00000910293, ENST00000910294, ENST00000910295, ENST00000910296, ENST00000910297, ENST00000910298, ENST00000910299, ENST00000910300, ENST00000910301, ENST00000910302, ENST00000910303, ENST00000910304, ENST00000910305, ENST00000940185, ENST00000940186, ENST00000956454, ENST00000956455, ENST00000956456, ENST00000956457, ENST00000956458

RefSeq mRNA: 4 — MANE Select: NM_001135032 NM_001135032, NM_001369524, NM_001369525, NM_032181

CCDS: CCDS1959

Canonical transcript exons

ENST00000393913 — 4 exons

Exon	Start	End
ENSE00000846784	75492318	75493609
ENSE00001045434	75522365	75522487
ENSE00001949001	75560680	75560939
ENSE00003649888	75518056	75518208

Expression profiles

Bgee: expression breadth ubiquitous, 165 present calls, max score 95.79.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.4590 / max 155.1186, expressed in 1179 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
29276	8.3532	1112
29278	5.6785	938
29275	0.2083	121
29277	0.0858	22
29273	0.0471	10
29281	0.0284	12
29272	0.0249	7
29280	0.0218	12
29274	0.0097	6
29279	0.0013	2

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	95.79	gold quality
cartilage tissue	UBERON:0002418	93.95	gold quality
liver	UBERON:0002107	93.68	gold quality
body of pancreas	UBERON:0001150	91.08	gold quality
metanephros cortex	UBERON:0010533	86.90	gold quality
pancreas	UBERON:0001264	86.51	gold quality
upper lobe of left lung	UBERON:0008952	85.66	gold quality
adult mammalian kidney	UBERON:0000082	85.52	gold quality
upper lobe of lung	UBERON:0008948	84.72	gold quality
placenta	UBERON:0001987	84.37	gold quality
spleen	UBERON:0002106	82.59	gold quality
right lung	UBERON:0002167	81.82	gold quality
lung	UBERON:0002048	81.44	gold quality
stromal cell of endometrium	CL:0002255	81.39	gold quality
islet of Langerhans	UBERON:0000006	81.35	gold quality
kidney	UBERON:0002113	80.00	gold quality
cortex of kidney	UBERON:0001225	79.63	gold quality
endocervix	UBERON:0000458	78.85	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	74.99	gold quality
palpebral conjunctiva	UBERON:0001812	74.96	gold quality
metanephros	UBERON:0000081	74.09	gold quality
pancreatic ductal cell	CL:0002079	73.91	silver quality
right uterine tube	UBERON:0001302	73.40	gold quality
lower lobe of lung	UBERON:0008949	72.40	gold quality
tibialis anterior	UBERON:0001385	71.90	silver quality
caput epididymis	UBERON:0004358	71.62	gold quality
parotid gland	UBERON:0001831	71.47	gold quality
corpus epididymis	UBERON:0004359	71.43	gold quality
ectocervix	UBERON:0012249	71.43	gold quality
left lobe of thyroid gland	UBERON:0001120	71.21	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	14.54

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

57 targeting EVA1A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-1290	99.59	69.90	2079
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-584-3P	99.35	67.69	1082
HSA-MIR-185-5P	99.35	68.60	2497

Literature-anchored findings (GeneRIF, showing 17)

• TMEM166 is a novel regulator involved in both autophagy and apoptosis. (PMID:17492404)
• TMEM166 expression was widely down-regulated in the cancer tissues. (PMID:22495369)
• Low TMEM166 mRNA and protein expression is associated with esophageal squamous cell carcinoma. (PMID:23098460)
• The adenovirus-mediated increase of FAM176A inhibited the growth of the tumor cells. (PMID:24257118)
• EVA1A interacts with the WD repeats of ATG16L1 through its C-terminal and promotes ATG12-ATG5/ATG16L1 complex recruitment to the autophagic membrane and enhances the formation of the autophagosome. (PMID:27490928)
• Low EVA1A expression is associated with glioblastoma. (PMID:28185834)
• results suggest that miR-125b plays a role in the resistance of HCC cells to chemotherapy via a mechanism involving the downregulation of EVA1A-mediated autophagy. (PMID:29749374)
• Myc/Max dependent intronic long antisense noncoding RNA, EVA1A-AS, suppresses the expression of Myc/Max dependent anti-proliferating gene EVA1A in a U2 dependent manner. (PMID:31754186)
• Eva1a ameliorates atherosclerosis by promoting re-endothelialization of injured arteries via Rac1/Cdc42/Arpc1b. (PMID:31977009)
• Eva-1 homolog A promotes papillary thyroid cancer progression and epithelial-mesenchymal transition via the Hippo signalling pathway. (PMID:32969138)
• Transmembrane Protein 166 and its Significance. (PMID:33006534)
• TMEM166 inhibits cell proliferation, migration and invasion in hepatocellular carcinoma via upregulating TP53. (PMID:33200377)
• Eva1a inhibits NLRP3 activation to reduce liver ischemia-reperfusion injury via inducing autophagy in kupffer cells. (PMID:33556710)
• The Degradation of TMEM166 by Autophagy Promotes AMPK Activation to Protect SH-SY5Y Cells Exposed to MPP(). (PMID:36078115)
• Down-regulation of EVA1A by miR-103a-3p promotes hepatocellular carcinoma cells proliferation and migration. (PMID:36273122)
• EVA1A (Eva-1 Homolog A) Promotes Endothelial Apoptosis and Inflammatory Activation Under Disturbed Flow Via Regulation of Autophagy. (PMID:36794585)
• Increased TMEM166 Level in Patients with Postoperative Stroke after Carotid Endarterectomy. (PMID:38734302)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	eva1a	ENSDARG00000061405
danio_rerio	EVA1A	ENSDARG00000067927
mus_musculus	Eva1a	ENSMUSG00000035104
rattus_norvegicus	Eva1a	ENSRNOG00000007118

Paralogs (1): EVA1B (ENSG00000142694)

Protein

Protein identifiers

Protein eva-1 homolog A — Q9H8M9 (reviewed: Q9H8M9)

Alternative names: Protein FAM176A, Transmembrane protein 166

All UniProt accessions (4): Q9H8M9, B8ZZF5, C9J5M4, C9JX09

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a regulator of programmed cell death, mediating both autophagy and apoptosis.

Subcellular location. Endoplasmic reticulum membrane. Lysosome membrane.

Tissue specificity. Expressed in lung, kidney, liver, pancreas, placenta, but not in heart and skeletal muscle.

Similarity. Belongs to the EVA1 family.

RefSeq proteins (4): NP_001128504, NP_001356453, NP_001356454, NP_115557 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR039500	EVA1_dom	Domain
IPR052461	EVA1_A/B	Family

Pfam: PF14851

UniProt features (9 total): region of interest 2, modified residue 2, chain 1, transmembrane region 1, compositionally biased region 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H8M9-F1	64.06	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 106, 114

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-8957275	Post-translational protein phosphorylation

MSigDB gene sets: 111 (showing top): GOBP_CARDIAC_CHAMBER_DEVELOPMENT, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, HNF3ALPHA_Q6, GOBP_CARDIAC_LEFT_VENTRICLE_MORPHOGENESIS, GOBP_CARDIAC_CHAMBER_MORPHOGENESIS, GOCC_VACUOLAR_MEMBRANE, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOBP_HEART_MORPHOGENESIS, OCT1_03, GOBP_CARDIAC_VENTRICLE_MORPHOGENESIS, GOBP_CARDIAC_VENTRICLE_DEVELOPMENT, AFP1_Q6

GO Biological Process (9): cardiac left ventricle morphogenesis (GO:0003214), energy reserve metabolic process (GO:0006112), autophagy (GO:0006914), apoptotic process (GO:0006915), post-embryonic development (GO:0009791), lung development (GO:0030324), TOR signaling (GO:0031929), connective tissue replacement (GO:0097709), heart development (GO:0007507)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): lysosomal membrane (GO:0005765), endoplasmic reticulum lumen (GO:0005788), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), lysosome (GO:0005764), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Metabolism of proteins	1
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
animal organ development	2
cardiac ventricle morphogenesis	1
energy derivation by oxidation of organic compounds	1
catabolic process	1
transmembrane transport	1
process utilizing autophagic mechanism	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
multicellular organism development	1
multicellular organismal process	1
respiratory tube development	1
respiratory system development	1
intracellular signal transduction	1
tissue remodeling	1
circulatory system development	1
binding	1
lysosome	1
lytic vacuole membrane	1
endoplasmic reticulum	1
intracellular organelle lumen	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
lytic vacuole	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

572 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EVA1A	ATG16L1	Q676U5	622
EVA1A	MPZL2	O60487	610
EVA1A	ATG5	Q9H1Y0	533
EVA1A	OSBPL3	Q9H4L5	500
EVA1A	TM9SF1	O15321	479
EVA1A	ATG4B	Q9Y4P1	475
EVA1A	SQSTM1	Q13501	474
EVA1A	GCFC2	P16383	468
EVA1A	TMEM59	Q9BXS4	467
EVA1A	AGBL5	Q8NDL9	436
EVA1A	NBR1	Q14596	429
EVA1A	ARPC1B	O15143	427
EVA1A	OSBPL6	Q9BZF3	425
EVA1A	ATG13	O75143	424
EVA1A	CASP3	P42574	423

IntAct

24 interactions, top by confidence:

A	B	Type	Score
GYPA	EVA1A	psi-mi:“MI:0915”(physical association)	0.670
GYPA	TCAF2	psi-mi:“MI:0914”(association)	0.640
SGTB	EVA1A	psi-mi:“MI:0915”(physical association)	0.560
MS4A13	EVA1A	psi-mi:“MI:0915”(physical association)	0.560
TSPAN4	EVA1A	psi-mi:“MI:0915”(physical association)	0.560
EDA	AP3B1	psi-mi:“MI:0914”(association)	0.530
		psi-mi:“MI:0914”(association)	0.350
BSCL2	QSOX1	psi-mi:“MI:0914”(association)	0.350
EFNB2	TCAF2	psi-mi:“MI:0914”(association)	0.350
P2RY1	GPC4	psi-mi:“MI:0914”(association)	0.350
PACC1	IPO5	psi-mi:“MI:0914”(association)	0.350
EVA1A	MTNR1B	psi-mi:“MI:0915”(physical association)	0.000
EVA1A	SGTB	psi-mi:“MI:0915”(physical association)	0.000
GYPA	EVA1A	psi-mi:“MI:0915”(physical association)	0.000
MS4A13	EVA1A	psi-mi:“MI:0915”(physical association)	0.000
TSPAN4	EVA1A	psi-mi:“MI:0915”(physical association)	0.000
EVA1A	PTN	psi-mi:“MI:0915”(physical association)	0.000
EVA1A	SUMO2	psi-mi:“MI:0915”(physical association)	0.000
SAT1	EVA1A	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): EVA1A (Two-hybrid), ATG16L1 (Reconstituted Complex), ATG16L1 (Affinity Capture-Western), MAP1LC3B (Reconstituted Complex), EVA1A (Positive Genetic), EVA1A (Proximity Label-MS), EVA1A (Two-hybrid), PTN (Two-hybrid), GYPA (Two-hybrid), SGTB (Two-hybrid), MS4A13 (Two-hybrid), TSPAN4 (Two-hybrid), LAMP2 (Co-fractionation), EVA1A (Co-fractionation), EVA1A (Co-fractionation)

ESM2 similar proteins: A0A1B0GU71, A6QPI4, B2RV13, D4A6L0, E1BBQ2, F1LQY6, G3UW36, O08856, P15382, P53801, P55199, P56182, Q08CB3, Q0VF94, Q148E1, Q17RQ9, Q2KJ58, Q32Q90, Q4R5F9, Q4V8A6, Q4VA36, Q5I0I4, Q5NVI6, Q5R8Q2, Q5T6X4, Q5T848, Q5XII8, Q68EN5, Q6P767, Q8C419, Q8CHT6, Q8R143, Q8R1T1, Q8TBN0, Q8VDV3, Q8WUX9, Q90YH8, Q91WM6, Q91ZP9, Q96IL0

Diamond homologs: O88917, O88923, O94910, O95490, O97817, O97827, O97831, P58658, P58659, P86178, Q08CB3, Q68US5, Q80TR1, Q80TS3, Q8JZZ7, Q8K2Y3, Q91WM6, Q9H8M9, Q9HAR2, Q9NVM1, Q9SCV9, Q9XU98, Q9Z173, B3MFV7, B3N8M1, B4HS00, B4J780, B4KMZ1, B4P3A0, Q292N4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	4
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

956 predictions. Top by Δscore:

Variant	Effect	Δscore
2:75518051:CCTA:C	donor_loss	1.0000
2:75518052:CTA:C	donor_loss	1.0000
2:75518053:TAC:T	donor_loss	1.0000
2:75518054:ACC:A	donor_loss	1.0000
2:75518055:CCTG:C	donor_loss	1.0000
2:75493610:C:CC	acceptor_gain	0.9900
2:75518204:CTCTT:C	acceptor_gain	0.9900
2:75518206:CTT:C	acceptor_gain	0.9900
2:75518207:TT:T	acceptor_gain	0.9900
2:75518209:C:CC	acceptor_gain	0.9900
2:75518213:T:C	acceptor_gain	0.9900
2:75522351:ATC:A	donor_gain	0.9900
2:75522486:CT:C	acceptor_gain	0.9900
2:75558636:A:C	donor_gain	0.9900
2:75560674:TCTTA:T	donor_loss	0.9900
2:75560675:CTTAC:C	donor_loss	0.9900
2:75560676:TTA:T	donor_loss	0.9900
2:75560677:TA:T	donor_loss	0.9900
2:75560678:ACCT:A	donor_loss	0.9900
2:75493606:TTTT:T	acceptor_gain	0.9800
2:75493606:TTTTC:T	acceptor_loss	0.9800
2:75493607:TTT:T	acceptor_gain	0.9800
2:75493608:TTCT:T	acceptor_loss	0.9800
2:75493609:TCTG:T	acceptor_loss	0.9800
2:75493610:CT:C	acceptor_loss	0.9800
2:75493611:T:A	acceptor_loss	0.9800
2:75517531:TTGA:T	donor_gain	0.9800
2:75518050:ACCT:A	donor_loss	0.9800
2:75518207:TTC:T	acceptor_loss	0.9800
2:75518208:TC:T	acceptor_loss	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000005417 (2:75540810 T>C), RS1000078635 (2:75552946 A>T), RS1000103183 (2:75492803 T>C), RS1000140244 (2:75569401 C>G,T), RS1000142590 (2:75517455 C>G,T), RS1000147106 (2:75528193 A>T), RS1000151585 (2:75511787 C>A), RS1000197533 (2:75522571 C>T), RS1000217501 (2:75521734 G>T), RS1000247092 (2:75551470 C>G), RS1000302108 (2:75557981 C>A), RS1000321131 (2:75518451 G>C,T), RS1000367177 (2:75565245 C>T), RS1000385542 (2:75524935 T>A), RS1000388335 (2:75504709 A>C)

Disease associations

OMIM: gene MIM:618990 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001762_51	Obesity-related traits	6.000000e-06
GCST001872_5	Presence of antiphospholipid antibodies	5.000000e-06
GCST002875_158	Diisocyanate-induced asthma	4.000000e-09
GCST005655_3	Seborrheic dermatitis	1.000000e-07
GCST007576_126	Chronotype	1.000000e-09
GCST010277_16	Gout	9.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006995	response to diisocyanate
EFO:0008328	chronotype measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	increases expression, decreases expression, affects cotreatment, decreases reaction	4
Benzo(a)pyrene	affects methylation, decreases expression	3
bisphenol A	decreases expression, affects cotreatment	2
(+)-JQ1 compound	decreases expression	2
Dexamethasone	decreases expression, affects cotreatment	2
Aflatoxin B1	affects expression, decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
FR900359	increases phosphorylation	1
quercitrin	decreases expression	1
trichostatin A	increases expression	1
arsenite	affects binding, increases reaction	1
sodium arsenite	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, affects cotreatment, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
K 7174	decreases expression	1
ICG 001	increases expression	1
darinaparsin	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	increases expression	1
Zoledronic Acid	decreases expression	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Caffeine	decreases phosphorylation	1
Calcitriol	decreases expression	1
Carbonyl Cyanide m-Chlorophenyl Hydrazone	affects cotreatment, increases localization	1
Chloroquine	decreases expression, decreases reaction, increases degradation	1
Cisplatin	affects cotreatment, decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E0CX	Ubigene HeLa EVA1A KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.